Receptor activator of nuclear factor-κB ligand (RANKL) as a novel prognostic marker in prostate carcinoma

Histology and Histopathology

Volumn 23, Issue 6, 2008, Pages 709-715

  Pérez Martínez, Francisco C ^a   Alonso, Verónica ^a   Sarasa, José L ^a   Manzarbeitia, Félix ^a   Vela Navarrete, Remigio ^a   Calahorra, Francisco J ^a   Esbrit, Pedro ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

Osteoprotegerin; Prognostic factors; Prostate carcinoma; PTHrP; RANKL

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE RELATED PROTEIN; PROSTATE SPECIFIC ANTIGEN; TNFSF11 PROTEIN, HUMAN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADENOCARCINOMA; AGED; ARTICLE; BLOOD; ENZYME IMMUNOASSAY; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSTATE; PROSTATE TUMOR; TUMOR RECURRENCE;

ADENOCARCINOMA; AGED; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PARATHYROID HORMONE-RELATED PROTEIN; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANK LIGAND; TUMOR MARKERS, BIOLOGICAL;

EID: 42149122104     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Amling C.L., Bergstralh E.J., Blute M.L., Slezak J.M. and Zincke H. (2001). Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J. Urol. 165, 1146-1151.
2. Asadi F. and Kukreja S. (2005). Parathyroid hormone-related protein in prostate cancer. Crit. Rev. Eukaryot. Gene Expr. 15, 15-28.
3. Bray F., Sankila R., Ferlay J. and Parkin D.M. (2002). Estimates of cancer incidence and mortality in Europe in 1995. Eur. J. Cancer 38, 99-166.
4. Brown J.M., Corey E., Lee Z.D., True L.D., Yun T.J., Tondravi M. and Vessella R.L. (2001). Osteoprotegerin and RANK ligand expression in prostate cancer. Urology 57, 611-616.
5. Chen G., Sircar K., Aprikian A., Potti A., Goltzman D. and Rabbani S.A. (2006). Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 107, 289-298.
6. Cohen B.L., Gomez P., Omori Y., Duncan R.C., Civantos F., Soloway M.S., Lokeshwar V.B. and Lokeshwar B.L. (2006). Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate cancer recurrence. Int. J. Cancer 119, 1082-1087.
7. Deftos L.J., Barken I., Burton D.W., Hoffman R.M. and Geller J. (2005). Direct evidence that PTHrP expression promotes prostate cancer progression in bone. Biochem. Biophys. Res. Commun. 327, 468-472.
8. Epstein J.I., Amin M., Boccon-Gibod L., Egevad L., Humphrey P.A., Mikuz G., Newling D., Nilsson S., Sakr W., Srigley J.R., Wheeler T.M. and Montironi R. (2005). Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand. J. Urol. Nephrol. Suppl. 216, 34-63.
9. Fata J.E., Kong Y.Y., Li J., Sasaki T., Irie-Sasaki J., Moorehead R.A., Elliott R., Scully S., Voura E.B., Lacey D.L., Boyle W.J., Khokha R. and Penninger J.M. (2000). The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103, 41-50.
10. Gleason D.F. (1992). Histologic grading of prostate cancer: a perspective. Hum. Pathol. 23, 273-279.
11. Hofbauer L.C., Neubauer A. and Heufelder A.E. (2001). Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer 92, 460-470.
12. Holen I., Croucher P.I., Hamdy F.C. and Eaton C.L. (2002). Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res. 62, 1619-1623.
13. Iddon J., Bundred N.J., Hoyland J., Downey S.E., Baird P., Salter D., McMahon R. and Freemont A.J. (2000). Expression of parathyroid hormone-related protein and its receptor in bone metastases from prostate cancer. J. Pathol. 191, 170-174.
14. Inoue H., Nishimura K., Oka D., Nakai Y., Shiba M., Tokizane T., Arai Y., Nakayama M., Shimizu K., Takaha N., Nonomura N. and Okuyama A. (2005). Prostate cancer mediates osteoclastogenesis through two different pathways. Cancer Lett. 223, 121-128.
15. Ito R., Nakayama H., Yoshida K., Kuraoka K., Motoshita J., Oda N., Oue N. and Yasui W. (2003). Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma. Virchows Arch. 443, 146-151.
16. Iwamura M., Abrahamsson P.A., Foss K.A., Wu G., Cockett A.T. and Deftos L.J. (1994). Parathyroid hormone-related protein: a potential autocrine growth regulator in human prostate cancer cell lines. Urology 43, 675-679.
17. Jones D.H., Nakashima T., Sanchez O.H., Kozieradzki I., Komarova S.V., Sarosi I., Morony S., Rubin E., Sarao R., Hojilla C.V., Komnenovic V., Kong Y.Y., Schreiber M., Dixon S.J., Sims S.M., Khokha R., Wada T. and Penninger J.M. (2006). Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440, 692-696.
18. Kokubo H., Yamada Y., Nishio Y., Fukatsu H., Honda N., Nakagawa A., Saga S., Tsuzuki T. and Hara K. (2005). Immunohistochemical study of chromogranin A in stage D2 prostate cancer. Urology 66, 135-140.
19. Landis S.H., Murray T., Bolden S. and Wingo P.A. (1999). Cancer statistics, 1999. CA Cancer J. Clin. 49, 8-31.
20. Lucia M.S. and Torkko K.C. (2004). Inflammation as a target for prostate cancer chemoprevention: pathological and laboratory rationale. J. Urol. 171, 830-835.
21. Neville-Webbe H.L., Cross N.A., Eaton C.L., Nyambo R., Evans C.A., Coleman R.E. and Holen I. (2004). Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res. Treat. 86, 269-279.
22. Pérez-Martínez F.C., Alonso V., Sarasa J.L., Nam-Cha S.G., Vela-Navarrete R., Manzarbeitia F., Calahorra F.J. and Esbrit P. (2007). Immunohistochemical analysis of low-grade and high-grade prostate carcinoma: relative changes of PTHrP and its PTH1 receptor, osteoprotegerin and receptor activator of nuclear factor-κB ligand. J. Clin. Pathol. 60, 290-294.
23. Rubio J., Ramos D., López-Guerrero J.A., Iborra I., Collado A., Solsona E., Almenar S. and Llombart-Bosch A. (2005). Immunohistochemical expression of ki-67 antigen, cox-2 and bax/bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens. Eur. Urol. 48, 745-751.
24. Seshasayee D., Wang H., Lee W.P., Gribling P., Ross J., Van Bruggen N., Carano R. and Grewal I.S. (2004). A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response. J. Biol. Chem. 279, 30202-30209.
25. Sobin L.H. and Wittekind C.H. (2002). TNM classification of malignant tumors. 6th ed. Wiley-Liss. New York.
26. Swindle P.W., Kattan M.W. and Scardino P.T. (2003). Markers and meaning of primary treatment failure. Urol. Clin. North Am. 30, 377-401.
27. Tovar Sepulveda V.A. and Falzon M. (2002). Parathyroid hormone-related protein enhances PC-3 prostate cancer cell growth via both autocrine/paracrine and intracrine pathways. Regul. Pept. 105, 109-120.
28. Wong B.R., Josien R., Lee S.Y., Sauter B., Li H.L., Steinman R.M. and Choi Y. (1997). TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J. Exp. Med. 186, 2075-2080.
29. Zhang J., Dai J., Qi Y., Lin D.L., Smith P., Strayhorn C., Mizokami A., Fu Z., Westman J. and Keller E.T. (2001). Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. Clin. Invest. 107, 1235-1244.
30. Zhang J., Dai J., Yao Z., Lu Y., Dougall W. and Keller E.T. (2003). Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Res. 63, 7883-7890.